Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Edwards Lifesciences (EW) is 9/10.
Edwards Lifesciences opened FY2026 with reported sales of $1.65 billion, up 12.7% on an underlying basis (about 16.7% as reported, aided by roughly 400 basis points of favorable foreign exchange), with broad-based strength across TAVR, TMTT, and Surgical. TAVR sales rose 11% to $1.2 billion on renewed clinical focus and long-term SAPIEN durability evidence, while TMTT surged approximately 42% to $173 million on EVOQUE, PASCAL, and the new SAPIEN M3. Adjusted EPS of $0.78 beat expectations and adjusted operating profit margin reached 31.4%, reflecting operating leverage and planned phasing of strategic investments, while GAAP EPS was $0.66. On the back of the Q1 outperformance, management raised full-year sales-growth guidance to 9%-11% and adjusted EPS guidance to $2.95-$3.05, and pointed to potential reimbursement tailwinds from the CMS TAVR NCD reconsideration and the new RAPID breakthrough-therapy policy.
Scored from Edwards Lifesciences’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $1.39B | +9.4% | $0.65 | +6.6% | 78.9% | 22.6% | 27.8% | $-177M |
| FY2025 Q1 | $1.41B | +6.2% | $0.61 | +5.2% | 78.7% | 27.9% | 25.3% | $224M |
| FY2025 Q2 | $1.53B | +10.6% | $0.56 | -8.2% | 77.6% | 28.1% | 21.5% | $241M |
| FY2025 Q3 | $1.55B | +14.7% | $0.50 | -90.3% | 77.9% | 27.4% | 18.7% | $516M |
| FY2025 Q4 | $1.57B | +13.3% | $0.16 | -75.4% | 78.3% | 23.6% | 5.8% | $354M |
| FY2026 Q1 | $1.65B | +16.7% | $0.66 | +8.2% | 78.2% | 31.2% | 23.1% | $-21M |
| FY2026 Q2 | $1.74B | +13.6% | $0.42 | -25.0% | 77.6% | 29.8% | 13.9% | — |